Laraflex en es it fr

Laraflex Brand names, Laraflex Analogs

Laraflex Brand Names Mixture

  • No information avaliable

Laraflex Chemical_Formula


Laraflex RX_link

No information avaliable

Laraflex fda sheet

Laraflex FDA

Laraflex msds (material safety sheet)

Laraflex MSDS

Laraflex Synthesis Reference

No information avaliable

Laraflex Molecular Weight

158.17 g/mol

Laraflex Melting Point

> 160 oC

Laraflex H2O Solubility

No information avaliable

Laraflex State


Laraflex LogP

No information avaliable

Laraflex Dosage Forms

Capsule; Drops; Liquid; Powder for solution; Solution; Tablet

Laraflex Indication

Used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

Laraflex Pharmacology

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Laraflex Absorption

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Laraflex side effects and Toxicity

Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Laraflex Patient Information

No information avaliable

Laraflex Organisms Affected

Humans and other mammals